Free tool
FAERS Monitor: Kyxata
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 219921 or its brand name (Kyxata, Carboplatin). Reports on generic versions are filed under their own applications.
Reports
130,077
Serious
124,012
95% of reports
Hospitalization
55,788
Death reported
20,461
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use8,814
- neutropenia7,633
- anaemia7,391
- nausea7,205
- febrile neutropenia6,742
- diarrhoea6,425
- malignant neoplasm progression6,347
- disease progression6,172
- thrombocytopenia6,085
- dyspnoea5,535
- vomiting5,279
- pyrexia4,983
- fatigue4,834
- drug ineffective4,483
- death4,378
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 1,263 |
| 2005 | 1,451 |
| 2006 | 1,358 |
| 2007 | 1,482 |
| 2008 | 1,356 |
| 2009 | 1,645 |
| 2010 | 1,876 |
| 2011 | 2,493 |
| 2012 | 3,407 |
| 2013 | 2,798 |
| 2014 | 2,638 |
| 2015 | 3,759 |
| 2016 | 4,289 |
| 2017 | 5,629 |
| 2018 | 7,631 |
| 2019 | 7,570 |
| 2020 | 7,832 |
| 2021 | 9,234 |
| 2022 | 11,523 |
| 2023 | 12,551 |
| 2024 | 13,571 |
| 2025 | 14,133 |
| 2026 | 10,587 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,924,082 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| febrile neutropeniaSignal | 6,742 | 18.2 | 17.7 | 98,629 |
| malignant neoplasm progressionSignal | 6,347 | 10.6 | 10.4 | 52,110 |
| neutropeniaSignal | 7,633 | 9.6 | 9.3 | 55,554 |
| thrombocytopeniaSignal | 6,085 | 9.2 | 9.0 | 42,542 |
| disease progressionSignal | 6,172 | 8.8 | 8.6 | 40,919 |
| anaemiaSignal | 7,391 | 6.5 | 6.3 | 33,210 |
| pyrexiaSignal | 4,983 | 2.3 | 2.3 | 3,863 |
| vomiting | 5,279 | 1.8 | 1.8 | 1,989 |
| off label use | 8,814 | 1.6 | 1.6 | 2,239 |
| diarrhoea | 6,425 | 1.6 | 1.6 | 1,539 |
| dyspnoea | 5,535 | 1.6 | 1.5 | 1,221 |
| nausea | 7,205 | 1.5 | 1.4 | 1,140 |
| fatigue | 4,834 | 1.0 | 1.0 | 0 |
| death | 4,378 | 0.8 | 0.8 | 178 |
| drug ineffective | 4,483 | 0.5 | 0.5 | 1,771 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.